Most people don’t realize that companies like 23andMe and Ancestry only look at less than 0.1% of your DNA. That’s because the technology they built on—microarrays—was the only affordable option when they launched over 15 years ago. But the cost of sequencing has entirely changed. Today, it’s possible to decode all six billion letters of your genome for the price of a lunch. At Nucleus, we’ve built from the ground up on full-genome sequencing technology—25,000 times more data than the typical consumer genetic test. That means you’re not just getting ancestry or shallow trait insights. You’re getting high-resolution assessments of disease risk, polygenic scores tied to complex traits like intelligence or muscle strength, and access to frontier research typically locked up in scientific journals or institutional databases. 

Why does this matter? Because knowing 0.1% of your DNA will only ever give you 0.1% of the picture. Your genome is not some static artifact. It's a dynamic circuit with billions of variables. And grasping complex traits requires deep, whole-genome analysis—not cherry-picked data from legacy platforms. 

We're not here to give you feel-good ancestry reports. We're here to build the future of personalized biology—and that starts with giving you everything science already knows about your DNA, not just what's convenient for old business models.

When you're chasing a mission as big as redesigning how people access and use their genetic information, you don’t wait for permission. You don’t need a fancy lab or a faculty grant. You need obsession. In Kian Sadeghi’s case, that obsession led him away from university lecture halls and straight into his childhood bedroom, where he filled 18 notebooks in a year-long dive into genome science, statistics, and programming. 

That journey didn’t start with funding or a team. It started with a deeply personal question—how does a healthy eight-year-old's cousin die in her sleep overnight?—and the answer his parents gave him: “bad genetics.” At every step, Kian doubled down. From engineering bacteria in a Brooklyn wet lab in high school to decoding the exponential drop in genome sequencing costs at Penn, he kept pushing further. Until finally, he dropped out and went inward.

Inside those four walls, he didn’t just analyze his own genome—he built the infrastructure that would become Nucleus. Not in theory. But in code, in hard science, and in learning to productize what he calls 'intellectual alpha.' He raised $300,000 before hiring a single employee. Cold emailed scientists whose research papers he had read from that very bedroom. And when the first $100,000 hit, there’s a Nest Cam clip of Kian literally sprinting out the front door.

Why are we telling you this?

Because Nucleus isn’t a cosmetic health app built off surface-level DNA testing. It's a platform grounded in the principle that the full genome matters, that personal agency starts with biological knowledge, and that consumer genomics should never be driven by fear—but by clarity. We combine whole genome data with non-genetic inputs to give people the most complete picture possible of their health risk—before any diagnosis—even if that picture starts in a bedroom in Brooklyn.

What if your next doctor’s visit didn’t start with, “Tell me what’s wrong,” but instead with, “We already know what you’re likely to face—and here’s what to do”? That’s not science fiction. It’s what we’re building.

The future of health isn’t reactive—it’s predictive and deeply personal. Using your DNA as the foundation, artificial intelligence allows us to layer real-time data from labs, wearables, lifestyle inputs, and family history to generate precision recommendations that are constantly updated and informed by genetic predispositions.

One example: If you have genetically high LDL cholesterol, most check-ups will flag the elevated result and suggest a drug. What if instead your platform contextualized the cholesterol spike with a polygenic risk score, compared it to people like you, and showed data-driven lifestyle interventions proven to work for your genotype? Maybe it’s a certain type of exercise, or diet guidance that goes far beyond “eat healthier.”

This level of specificity is only possible when we integrate AI with the science of statistical genetics. AI is reductionist unless it knows what inputs matter. At Nucleus, we’re building the infrastructure to fuse those data layers into a live model that adapts as you evolve. The promise of precision medicine doesn’t lie in a static DNA report. It lives in the ability to translate that report into dynamic action—what to eat, when to test, how to train—and refine that over time.

The hard part isn’t just the science. It’s aligning everything from clinical operations to UX design to regulatory strategy to deliver this in a way that people understand and trust. Our challenge isn’t creating the tech. It’s building the entire castle, layer by layer.

This is the shift from understanding to action. From “you have a high genetic risk for disease” to “here’s exactly how people with your biology have improved outcomes—and how you can too.”

You don’t wake up one morning with disease. Disease begins with invisible signals—molecular shifts that start long before clinical symptoms show up. The future of healthcare isn’t pills or procedures. It’s prediction. True prevention will come from tracking molecular data in real time.

At Nucleus, we believe your health data should not wait until something breaks. With full-genome sequencing at birth and continuous monitoring of molecular signals, we can detect patterns before illness emerges. Small changes in molecular biomarkers—just like elevated heart rate during sleep—can provide early insight far ahead of diagnosis.

Imagine an ecosystem where an AI overlays your genetic data, nutrition, daily activity, and biomarkers to constantly update live risk scores. Not a doctor’s visit. Not a reactive test. But health intelligence always-on. This isn’t sci-fi. The building blocks are already here.

We’ve seen early glimpses with companies like Eight Sleep identifying anomalies days before symptoms arise. Now picture that signal not limited to heart rate, but across hundreds of markers, layered with your unique genetic predispositions.

This is the foundation we’re building at Nucleus. DNA is just the start. The real upside comes from the molecular level—tracking, learning, and adjusting dynamically. That level of precision could become the greatest disease prevention system humans have ever had.

We need to move away from episodic medicine and into holistic, longitudinal, genetically-informed care. And that shift requires not just new tools, but a new way of thinking about early detection and true prevention.

Carrier screening is one of the most overlooked applications of genomic science, but it has the power to quietly eliminate entire classes of rare, inherited diseases. Here’s what most people miss: Every person, whether or not they show symptoms, can carry a genetic variant that increases risk for recessive conditions. When both parents unknowingly carry the same gene mutation, their child can inherit a serious disease—and it’s entirely preventable.

That’s where carrier screening comes in. It’s not speculative, it’s not experimental. It’s basic Mendelian genetics that’s been taught in classrooms for decades. Now, with population-scale sequencing becoming more accessible, we’re moving toward a world where both partners can get sequenced before having children. From there, it's a simple Punnett square to understand potential risks. And when you have that information, you get agency. You can make informed reproductive choices.

With widespread adoption, we’d see the gradual elimination of many monogenic diseases from the population. It’s hard to overstate the impact of that. We’re talking about preventing suffering and improving quality of life—not for one person, but across generations. And this doesn’t require futuristic bioengineering. It just requires society to realize the tools are already here.

At Nucleus, this forms a core part of our vision: giving people early access to their biological data in ways that are actionable, responsible, and ethical. Carrier screening isn’t about designing babies. It’s about preventing avoidable tragedy. It’s time we stop treating this like an edge case in prenatal care and start treating it as the new standard.

Every founder has a reason. For some, it’s about solving a problem. For others, it’s ambition. For me, it’s fear and love.

I think obsessively about the consequences of getting it wrong. We’re building at the edge of genetic science—where one mistake could mean irreversible outcomes. But that fear doesn’t paralyze me. It sharpens everything. It forces clarity. It sets the bar high for cautious, deeply research-backed innovation.

Then there’s love. Love for science. For the art of building something from nothing. For the strange magic where computation meets biology. That emotional undercurrent is real and it’s relentless. It’s why I’m up at 11pm on notebook page 249, thinking through unintended interactions in polygenic risk scores or the edge cases in variant interpretation.

That dual engine—fear and love—is why our focus at Nucleus doesn’t shift with the hype cycles. Whether the rest of the world cares or not, whether it’s a hot market or a quiet one, we are locked in. The stakes are too high, and the opportunity too meaningful, to be distracted by buzz.

We’re not building genomic tools because it’s trendy. We’re building because people have a right to know their full biological picture. And no one else is giving that access in a way that’s personal, safe, and grounded in science.

If you’re someone who runs on fear and love too—if you see this work as both responsibility and calling, not trend—you belong in this conversation. We need more people obsessing for the right reasons.

Most DNA tests analyze just 0.1% of your genome. Nucleus reads 100%—every single base pair. That’s 25,000 times more data. More accuracy. More power in your hands.

Started in my childhood bedroom with 18 notebooks and a $100K cold email. Today, people use Nucleus to proactively screen for cancer, understand disease risk, and plan their families — all from a single test. This isn’t just a startup. It’s personal.

You know more about your car than your own body. That’s about to change.

Your genome can now trigger real-time health advice: 'You’re in the 90th percentile for high cholesterol. People like you see results from 3 Peloton sessions a week. Skip the steak tonight.'

We're not guessing. We're calculating.

Your body knows you’re sick before you do. Real-time molecular tracking can catch disease *before* symptoms appear. Imagine diagnosing covid 24 hours before a cough. That’s not sci-fi. It’s what the future of genomics will enable. And we’re building it.

If both parents are carriers, their child could inherit a serious disease with just a coin-flip’s chance. This isn’t theoretical. It’s eighth-grade biology. Carrier screening makes these risks visible—before decisions are made. This is how genetic disease disappears in a generation.

You can’t build a company like Nucleus without being obsessed. Part science, part soul. A kind of fear pushes you—fear of letting down the people who sacrificed so you could even try. But it’s love that sustains you. Love for the raw beauty of creation. That’s the real engine.

Most companies only look at 0.1% of your DNA. Nucleus reads the entire genome. Six billion letters. That's the difference between a snapshot and seeing the whole picture.

Start with Kian spelling out the cost of sequencing in 2006 and why older companies had to cut corners. Then transition to the moment he reveals today’s cost to sequence everything and how Nucleus gives people access to far more accurate data.

End on him hitting the core insight: Nucleus delivers the full scientific frontier — not a filtered version.

What kind of person drops out of college to study their own genome and ends up building a company out of a childhood bedroom? This is how Nucleus started: not in a lab, not with a cofounder, but with an obsession. Kian’s story isn’t about overnight success. It’s about stuffing 18 notebooks with genetics, statistics, and code. It’s about realizing the genome was dropping in cost faster than Moore’s Law and deciding to chase that future alone. You don’t wait for someone to give you permission to build something like this. You live it. You breathe it. You build it until an investor hears the vision and sends $100K. And that’s just chapter one.

Why does it take artificial intelligence to truly understand the body that created it? Kian breaks down how AI, layered on top of your genome, is finally closing the prediction gap in healthcare. This isn’t wearables or step trackers. This is your DNA fused with real-time health data—steering everything from your grocery cart to your Peloton schedule. The more AI sees of your biological circuit board, the more precise your daily medical decisions become.

What if your body knew you were getting sick before you did?

You wake up feeling totally fine. But your heart rate is spiking. It happened to me. A full 24 hours later, I was flat-out sick. The signal was there before the symptoms. Now imagine tracking every molecular signal from birth. Heart rate, sleep cycles, metabolism, tiny genetic shifts—all syncing in real time.

That’s not science fiction. That’s the future we’re building. The point isn’t just tracking. It’s understanding. Predicting. Preventing. That’s real health—before there’s ever a single symptom.

What if we could eliminate entire categories of disease before a child is even born? Kian breaks down the power of carrier screening and why soon every parent will know what they’re passing on. This isn’t speculative. It’s basic inheritance. If both parents carry the gene, there’s a 1 in 4 chance the child will too. But if you know in advance, that risk can be avoided completely. For some families, this changes everything.

What does it take to stay locked in when the world isn’t watching? Fear that you’ll fail. Love for a mission that matters. This clip pulls back the curtain on what fuels the intensity behind building Nucleus. Kian talks about the weight of expectations, the pressure of immigrant sacrifice, and how both the beauty and the terror of the mission keep him chasing it—relentlessly.

Start with the guest’s shocked reaction that other companies know more about you than you do. Then let Kian break down how genome sequencing went from $10 million to $3.99. Emphasize that legacy DNA companies are only reading 0.1% of your DNA. Nucleus reads 100%. This is the moment where viewers realize they’ve barely scratched the surface of their DNA. End on Kian explaining that with access to all 6 billion letters, Nucleus gives people far more accurate insights into their health, traits, and risk factors.

A first-gen kid drops out of college, locks himself in his childhood bedroom for a year, self-teaches computational genetics, fills 18 notebooks, and ends up launching a company with VC money off a cold DM. This isn’t a movie. It’s how Nucleus started.

Start with Kian laying out this wild idea: a platform tells you your LDL is high, shows it’s genetic, then recommends changing your Peloton routine and skipping the ribeye and white rice at Whole Foods. Keep the viewer anchored with the shock factor of that ultra-personalized health feedback loop. Lean into how AI connects your genome to daily life choices in real time. Close on the idea that AI might soon understand your own body better than you do—not because it’s smarter, but because it sees the patterns you can’t.

You don’t just wake up sick one day out of nowhere. Your body was already warning you. Most people never see it because they’re not looking at the right level. But what if your health data tracked you in real time—down to your molecular signals? That moment before symptoms even start? That's the future. The heart rate spike before the fever. The genetic whisper before the disease. Our bodies talk way before we listen.

Start with the question: What if genetic diseases could be taken off the map for future generations? The video kicks in as Kian explains how every parent could make informed decisions just by sequencing their DNA. He dives into Punnett squares, inherited conditions, and how simple it actually is to avoid passing on certain diseases. The moment hits when he points out that this is 8th-grade science, yet society still isn’t using this power. Close it as he envisions a world where monogenic diseases are essentially eliminated—just by people having access to their own data.

Start with Kian being asked why he's so intensely focused on building Nucleus. Let that moment hang. Then shift into his raw answer: it’s not just love for the science — it’s fear too. Show the tension between loving what you do and being terrified of failing the people who sacrificed everything for you. Let that weight hit. Cut with him reflecting on being alone with doubt at 11 PM, tapping through notebook page 249. End right before the conversation pivots to team recruitment, leaving the viewer with a chill and the question, what's pushing them this hard?

Everyone thinks they've gotten their DNA sequenced. But they’ve only seen 0.1% of it. Legacy companies never gave you the full picture. Nucleus? We decode all 6 billion letters. That’s 25,000 times more data. More traits, more risk insights, more truth about who you are.

20 years old. Bedroom in Brooklyn. A stack of notebooks and an obsession with one question: can I read my own genome? Kian ditches college, dives deep into self-study, and fills 18 notebooks with genetics, stats, code. Then he cold texts an investor. $100K lands. Nucleus is born. That’s not a garage story. That’s a whole different engine.

Most people know more about their car than their own body. We’re flipping that. Imagine an AI that knows your DNA, flags your cholesterol before it’s a problem, and tells you what to fix in your lifestyle before a doctor ever calls. Not just general advice—advice built for your genetic code. That’s the future we’re building.

Most people still wait to get sick before doing anything about their health. But on a long enough timeline, that mindset becomes deadly. What if the future of healthcare isn't treatment at all, but real-time molecular tracking—before symptoms even show up? Kian breaks down how the most advanced consumer health platforms will detect disease before you feel a thing. This is about catching the signal before the cough, the shift before the collapse. This is how we actually prevent disease.

Almost every genetic disease we pass to our kids comes down to one thing: inheritance. If both parents carry the same faulty gene, your child has a real chance of inheriting that disease. But here’s what most people don’t realize: it’s avoidable. Carrier screening can identify that risk before you even try to have a child. This isn’t some futuristic tech. It’s here. And if we made it standard, we could literally eliminate entire categories of genetic disease—permanently. That future is on the table. Question is: are we paying attention?

Love built Nucleus. Fear fuels the focus. In this moment, Kian opens up about the pressure of being a first-gen founder, the sacrifices his parents made, and the terrifying doubts that creep in when you're building something this big alone late at night. But right next to that fear is love for science, product, and the raw act of creation. It's how obsessive focus is born. And why this mission is personal.

Most consumers have no idea they're only getting 0.1% of their DNA analyzed.

That decision wasn’t just about cost. It was a philosophy. Legacy genomics companies built their models around simplicity, conservatism, and constraint—showing customers only a partial view of their own genome.

But that model is outdated. The full genome can now be sequenced at a fraction of what it used to cost, and the science behind complex traits has matured. We’ve moved from single-gene theories to models that look at thousands of interacting variants.

At Nucleus, we’re sequencing 100% of your genome—25,000x more data than others. Because we believe healthcare decisions, scientific inquiry, and personal agency all start with full access, not filtered access.

We don’t hide from complexity. We present it with transparency, and trust people to rise to it.

I left college to move back into my childhood bedroom, not because I had a startup idea, but because I couldn’t stop thinking about a single chart.

It showed the cost of sequencing a human genome dropping from $1 billion to $1,000. Faster than Moore’s Law. What happens when it hits $100? Or $10?

Most people saw a stat. I saw the future. And I couldn’t unsee it.

That year, I filled 18 notebooks teaching myself everything from genetic statistics to genome visualization. I built myself up to the intellectual frontier—the spot in the forest no one else had mapped yet.

That’s where Nucleus began.

Not in a garage. In a Brooklyn bedroom, with just a laptop, an unhealthy amount of determination, and a vision of marrying scientific depth with mass accessibility. 

We weren’t chasing a trend. We were building infrastructure for the future of health agency.

Years later, I still believe the truest product is built when your curiosity consumes you first.

Most people know more about their car than they do about their own body. But that’s starting to change.

At Nucleus, we’re designing a system where your genome, bloodwork, lifestyle, and medical history don’t sit in silos—they talk to each other.

AI isn’t just another tool. When paired with genomics, it’s the key to bridging the gap between what your DNA says and what your body actually does. That means real-time, personal health guidance: what to eat, how to train, when to get screened—and why.

We’re not just predicting disease risk. We’re nudging decisions. The long tail of human health isn’t passive anymore. It’s something we can plot, optimize, and change.

This synthesis of predictive AI and genetic engineering is one of the most consequential junctions in modern medicine. And we’re just getting started.

There’s a type of disease prevention that doesn’t wait for symptoms — it sees them coming before they surface.

If you zoom out and think about health not as a symptom response system, but as a constant molecular readout, everything changes. Because long before you feel sick, your body is already speaking — quietly, measurably. That’s where the future of healthcare is heading.

I’ve personally seen this happen with something as simple as overnight biometric tracking. One night, I woke up to a 50% spike in resting heart rate — no symptoms, felt fine — but the next day, I was knocked out by a virus. The signal came first, the sickness second.

Now imagine running that same concept across your entire molecular profile: genomics, blood biomarkers, gut microbiome, everything. Continuously. In real time. An AI layer constantly learning and adjusting your health forecast based on every bite of food, every workout, every change in your body. Not just reactive but predictive.

That’s not sci-fi. It’s where we’re going at Nucleus. Real-time molecular tracking is how we shift from managing disease to preventing it — before it ever has a chance to surface.

Carrier screening is one of the most underutilized tools in modern medicine. Most people don't realize they’re carriers for genetic conditions—until they pass them on. But if both parents are sequenced ahead of time, we can dramatically reduce the number of babies born with preventable monogenic diseases. This isn’t futuristic. The science is here. The cost curve is dropping. What’s missing is awareness.

At Nucleus, we believe every prospective parent should be equipped with this knowledge well before conception. Because when you understand inheritance, you can change lives across generations. The idea that you might quietly carry a devastating condition—and never know it until your child suffers from it—is a gap we can close.

We’re building the tools that will make this conversation a normal part of planning a family. It’s time.

Every founder has a core driver. Mine sits in that razor-thin space between fear and love.

Fear of wasting the sacrifice my parents made to get here. Fear of failure after walking away from a top university to chase something nobody could see yet.

And love for the craft. For the work. For the ability to turn zero into one through science and relentless product thinking.

That combination builds a type of focus you can’t fake. We’re not following hype cycles. We’re pushing the frontier of genomics quietly, obsessively. Because when what you’re building could fundamentally change how humanity understands and manages disease, distraction isn’t an option.

Nucleus is a mission company. Built by people who feel that same internal pressure not to look away from what matters. If that resonates with you, we should talk.